Blum Holdings, Inc. operates in the specialty and generic drug manufacturing sector, focusing on niche therapeutic areas such as oncology and neurology. The company's competitive position is bolstered by its proprietary drug formulations and a strong pipeline of FDA-approved products, primarily targeting the U.S. market.
Business Overview
Blum Holdings generates revenue through the sale of specialty and generic drugs, leveraging its proprietary formulations to maintain pricing power in competitive therapeutic areas. The company benefits from a strong patent portfolio and strategic partnerships with healthcare providers, enhancing its market reach.
FDA approval of new drug formulations
Changes in healthcare regulations impacting drug pricing
Market share shifts in oncology and neurology segments
Partnership announcements with healthcare providers
Risk Factors
Regulatory changes affecting drug pricing and approval processes
Technological disruption in drug development methodologies
Increased competition from generic drug manufacturers
Emergence of biosimilars in specialty drug markets
Negative operating cash flow impacting liquidity
High operational leverage leading to volatility in earnings
Macro Sensitivity
moderate - The healthcare sector is somewhat insulated from economic downturns, but demand for specialty drugs can be affected by consumer spending and insurance coverage.
Rising interest rates could increase the company's financing costs, impacting its ability to invest in R&D and potentially compressing margins due to higher operational costs.
minimal - The company operates with a negative debt/equity ratio, indicating a lack of reliance on external financing.
Profile
growth - Investors are likely attracted to potential upside from new drug approvals and market expansion.
high - The stock has exhibited significant volatility, particularly with a 1-year return of -74.3%.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
